Company:Array BioPharma
| NASDAQ: ARRY Russell 2000 Component | |
| Headquarters | Boulder , |
Array BioPharma is a U.S.-based, clinical stage, publicly traded pharmaceutical company founded in Boulder, Colorado[1] (NASDAQ:ARRY)[2] that is included in the NASDAQ Biotechnology Index.[3]
The company has engaged in collaborations with Pfizer and Merck to study several cancer targeting drug combinations.[4][5] In July 2013 the company partnered with Loxo Oncology to develop cancer drugs[6], in November 2015 the company partnered with Pierre Fabre[7] and the company also partnered with Ono Pharmaceutical in March 2016 to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.[8][9]
In 2017 it spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.[1]
In March 2018 Array sued AstraZeneca for breach of contract, saying that AZ owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AZ in a deal for selumetinib, which Array said it had licensed to AZ in 2003.[10]
In June 2018, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) were approved by the FDA for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.[11]
References
- ↑ 1.0 1.1 Castle, Shay (December 26, 2017). "Boulder’s Array BioPharma spins out subsidiary to develop rare-disease drugs". The Denver Post. https://www.denverpost.com/2017/12/26/boulder-array-biopharma-rare-disease-subsidiary/.
- ↑ "Array BioPharma Inc. (ARRY)". NASDAQ OMX Group. http://www.nasdaq.com/symbol/arry. Retrieved 3 January 2016.
- ↑ "^NBI Components NASDAQ Biotechnology Stock - Yahoo! Finance". Yahoo Finance. https://finance.yahoo.com/q/cp?s=%5ENBI. Retrieved 5 June 2017.
- ↑ Al Idrus, Amirah (December 19, 2017). "Array Biopharma ties up with Pfizer on cancer-fighting combos". =FierceBiotech. https://www.fiercebiotech.com/biotech/array-biopharma-ties-up-pfizer-cancer-fighting-combos.
- ↑ Hughes, Emily (6 June 2016). "Merck, Pierre Fabre and Array BioPharma collaborate for cancer drug clinical trial" (in en-gb). EPM Magazine. https://www.epmmagazine.com/news/merck-pierre-fabre-and-array-biopharma-collaborate-for-cance/.
- ↑ "Array, Loxo Ink $434M+ Deal for Small Molecule Cancer Drug Development". Genetic Engineering News. July 10, 2013. https://www.genengnews.com/gen-news-highlights/array-loxo-ink-434m-deal-for-small-molecule-cancer-drug-development/81248580.
- ↑ Lawrence, Stacy (September 26, 2016). "Array up by more than half on PhIII melanoma combo data". FierceBiotech. https://www.fiercebiotech.com/biotech/array-up-by-more-than-half-phiii-melanoma-combo-data.
- ↑ Taylor, Phil (May 31, 2017). "Array adds Ono as Japanese partner for MEK/BRAF combo". FierceBiotechm. https://www.fiercebiotech.com/biotech/array-adds-ono-as-japanese-partner-for-mek-braf-combo.
- ↑ Vinluan, Frank (June 1, 2017). "Array Lands $31M in Licensing Deal with Japan’s Ono Pharma". Xconomy. https://www.xconomy.com/boulder-denver/2017/06/01/array-lands-31m-in-licensing-deal-with-japans-ono-pharma/.
- ↑ Vogt, RJ (March 19, 2018). "AstraZeneca Owes $192M For Cancer Drug Rights, Rival Says" (in en). Law360. https://www.law360.com/articles/1023948/astrazeneca-owes-192m-for-cancer-drug-rights-rival-says.
- ↑ "Press release: FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations". FDA. June 27, 2018. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm.
 |
